US Patent

US10716777 — Antitumoral use of cabazitaxel

Method of Use · Assigned to Sanofi Mature IP · Expires 2030-10-27 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of cabazitaxel in combination with prednisone or prednisolone for treating prostate cancer, particularly metastatic prostate cancer.

USPTO Abstract

The invention relates to a compound of formula: which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.

Drugs covered by this patent

Jevtana Kit (cabazitaxel) · Accord Hlthcare

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2856`	—	Jevtana Kit

Patent Metadata

Patent number: US10716777
Jurisdiction: US
Classification: Method of Use
Expires: 2030-10-27
Drug substance claim: No
Drug product claim: No
Assignee: Sanofi Mature IP
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.